Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.
Read MoreLatest News
Xenon Reports Third Quarter 2025 Financial Results & Business Update
Xenon to Report Q3 2025 Financial Results on November 3, 2025
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View All News >
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
